Area of research
Genetics · Epidemiology
Research interest
Research focused on Infliximab and Inflammatory bowel disease, with related work in Ulcerative colitis, Crohn's disease, Homeostasis. Notable publications include 'A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis', 'Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis', and 'A20 controls intestinal homeostasis through cell-specific activities'.
Risk Stratification for Surgery in Stricturing Ileal Crohn’s Disease: The BACARDI Risk Model
Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn’s disease
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab
A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease
Prognostic factors for long‐term infliximab treatment in Crohn's disease patients: a 20‐year single centre experience
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis
Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease
Immunogenicity to infliximab is associated with HLA-DRB1
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn’s Disease
A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis
A20 controls intestinal homeostasis through cell-specific activities
Targeting TNF-α for the treatment of inflammatory bowel disease
Infliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel Disease